Business Context and Reporting Period
Company: Nektar Therapeutics
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2007
Business Overview: Nektar is a biopharmaceutical company focused on Pulmonary Technology and PEGylation Technology. The company relies heavily on its collaboration with Pfizer for the manufacturing and sale of Exubera (inhaled insulin), which accounted for 76% of total revenue in the quarter. The company operates in a single business segment and is currently in a net loss position, funded by cash reserves and debt financing.
Key Financial Metrics
| Metric (in thousands) | Q1 2007 | Q1 2006 |
|---|---|---|
| Total Revenue | $85,016 | $28,959 |
| Net Loss | $(25,673) | $(33,471) |
| Loss Per Share (Basic/Diluted) | $(0.28) | $(0.38) |
| Operating Cash Flow | $(28,997) | $(38,718) |
| Cash & Cash Equivalents | $83,140 | $261,273 (Beginning of period) |
| Total Investments | $315,187 | $394,880 |
| Total Debt (Convertible Notes) | $381,627 | $417,653 |
| Working Capital | $380,101 | $369,725 |
Note: Working Capital calculated as Total Current Assets minus Total Current Liabilities.
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased 194% to $85.0 million, driven primarily by a $60.1 million increase in product sales and royalties. This was largely due to a change in revenue recognition policy for Exubera (recognizing revenue upon shipment rather than after a 60-day return period) and increased shipment volumes.
- Improved Net Loss: Net loss narrowed by 23% to $25.7 million, despite higher operating costs. The improvement was aided by the revenue recognition change and a reduction in general and administrative expenses.
- Debt Reduction: The company repaid $36.0 million of its 5% convertible subordinated notes in February 2007, reducing total convertible notes outstanding from $417.7 million to $381.6 million.
- Inventory Build-up: Inventory increased to $16.8 million from $14.7 million, reflecting raw materials and work-in-process for PEGylation products and Exubera components.
Outlook, Risks, and Management Commentary
- Exubera Commercialization: Pfizer's commercial launch of Exubera is in early stages and has been slower than anticipated. Pfizer has built substantial inventory, leading Nektar to reduce manufacturing volumes in the second half of 2007 and 2008. Future revenue visibility is limited as Pfizer controls sales and marketing.
- Manufacturing Disruption: A fire at the San Carlos manufacturing facility in February 2007 caused a brief closure, resulting in an estimated $2.2 million loss in product revenue and a $1.7 million negative impact on gross margin. The company intends to seek recovery via business interruption insurance.
- Liquidity and Debt: As of March 31, 2007, the company held approximately $398.3 million in cash and investments against $411.3 million in total indebtedness. A significant debt obligation of $66.6 million (3.5% notes) is due in October 2007. Management is evaluating spending reductions and potential restructuring charges.
- Legal Risks: Novo Nordisk has sued Pfizer alleging patent infringement regarding Exubera. While Nektar is not a named party, it faces potential indemnity claims and litigation costs. Additionally, Nektar has a settlement obligation of $10 million payable over ten years to the University of Alabama Huntsville.
- Accounting Changes: Adoption of FIN 48 (Accounting for Uncertainty in Income Taxes) had no immediate impact. The change in Exubera revenue recognition policy increased gross margin by $5.2 million and reduced net loss per share by $0.06 for the quarter.
Investor Verification Checklist
- Debt Maturity: Verify the company's ability to refinance or repay the $66.6 million convertible note due in October 2007 given current cash burn rates.
- Exubera Sales Velocity: Monitor Pfizer's sales data and inventory levels to assess the sustainability of Nektar's manufacturing revenue, which is currently depressed due to Pfizer's inventory overhang.
- Insurance Recovery: Confirm the status of the business interruption insurance claim regarding the $2.2 million revenue loss from the San Carlos fire.
- Legal Exposure: Track the progress of the Novo Nordisk vs. Pfizer litigation to estimate potential indemnification liabilities for Nektar.
- Cost Reduction Plan: Watch for announcements regarding the "review and evaluation phase" of expenditure reductions, which could lead to restructuring charges in Q2 2007.